Immunic Inc

Immunic Inc maintains a strong liquidity position, with cash and equivalents amounting to $79.698 million, representing 92.0% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a debt-free capital structure. The current ratio of 3.75 suggests the company has sufficient short-term assets to cover its liabilities. The company is currently unprofitable, with a net loss of $21.38 million and an operating loss of $22.814 million in the latest period. Return on equity (ROE) is -33.63%, and return on assets (ROA) is -24.72%, both significantly below the industry median for biotechnology firms. The negative EBITDA multiple of -4.06 further underscores the company's lack of profitability. Immunic's revenue is not disclosed in the provided data, and the company does not report segment or geographic revenue breakdowns. As a pre-revenue biotechnology firm, its operations are concentrated in research and development, with no disclosed geographic diversification. The company is in a high-growth phase, with a market price target of $49.00 from analysts, significantly above the current market price of $12.65. The mean recommendation of 1.56 (on a 1-5 scale) indicates a strong buy consensus among analysts. However, the company has not provided forward-looking revenue guidance, and its growth is contingent on successful clinical trials and regulatory approvals. Risk factors include the absence of revenue and the high costs associated with drug development. The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is assessed as low. However, the company may need to raise additional capital to fund operations, which could lead to future dilution. Recent events include the continued development of its clinical-stage pipeline, with no major regulatory or legal issues reported in the latest filings. Analysts have expressed optimism about the company's long-term potential, but the near-term financial outlook remains challenging.